Title:
ANTI-α-V INTEGRIN ANTIBODY FOR TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERS
Document Type and Number:
Japanese Patent JP2022022217
Kind Code:
A
Abstract:
To treat fibrosis and/or fibrotic diseases by means of antibodies.SOLUTION: The invention relates to the administration of an anti-α-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of the antibody. Even more specifically, the invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting αv-integrins to patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-α-v integrin antibody DI17E6 and structural mutants or modifications thereof.SELECTED DRAWING: None
Inventors:
ILHAN CELIK
EIKE STAUB
MIRIAM URBAN
SABINE RAAB
EILEEN SAMY
ANDREW BENDER
GEORGIANNA HIGGINBOTHAM
WU YIN
XU DAIGEN
EIKE STAUB
MIRIAM URBAN
SABINE RAAB
EILEEN SAMY
ANDREW BENDER
GEORGIANNA HIGGINBOTHAM
WU YIN
XU DAIGEN
Application Number:
JP2021181951A
Publication Date:
February 03, 2022
Filing Date:
November 08, 2021
Export Citation:
Assignee:
MERCK PATENT GMBH
International Classes:
A61K39/395; A61K31/365; A61K31/519; A61K31/573; A61P1/16; A61P9/00; A61P11/00; A61P13/12; A61P17/00; A61P43/00; C12N15/12; C12Q1/68
Domestic Patent References:
| JP7034914B2 | 2022-03-14 |
Foreign References:
| WO2014138906A1 | 2014-09-18 |
Other References:
AUSRA MILANO; ET AL: "MOLECULAR SUBSETS IN THE GENE EXPRESSION SIGNATURES OF SCLERODERMA SKIN", PLOS ONE, vol. 3, no. 7, JPN5018008009, 16 July 2008 (2008-07-16), pages 2696 - 1, ISSN: 0004932332
Attorney, Agent or Firm:
Aoki Atsushi
Shinji Mihashi
Youichi Watanabe
Nakajima Masaru
Ryotaro Takei
Tatsunori Ikeda
Shinji Mihashi
Youichi Watanabe
Nakajima Masaru
Ryotaro Takei
Tatsunori Ikeda